The FDA has recently approved (Aug. 2012) a new drug to help in the treatment of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation. Linzess (linaclotide), manufactured by Ironwood Pharmaceuticals and Forest Laboratories, is a once daily oral medication available for adults of either sex to help alleviate the pain and constipation in IBS-C patients and those with CIC (chronic idiopathic constipation). IBS-C is defined as recurring abdominal pain associated with constipation. CIC or chronic idiopathic constipation is defined as constipation that is long lasting or continuously reoccurring.
Linzess works by increasing fluid secretion in the intestine. This aids in easier transit of stool. Linzess also relieves abdominal pain caused by the sensitive nerve endings in the intestines of IBS and CIC patients.
IBS-C symptoms relieved with Linzess include:
1. abdominal pain
2. constipation
3. infrequent and incomplete bowel movements
CIC symptoms relieved with Linzess include:
1. constipation
2. hard stools
3. infrequent and incomplete bowel movements
Linzess is taken once daily 30 minutes before the first meal of the day. The recommended dosage is 290mcg a day for IBS-C patients and 145mcg a day for CIC patients. Diarrhea is the most common side effect.
Linzess is not a laxative. It is not safe for children under 17 years of age.
For more information, visit the official site on Linzess.
Always consult a physician before taking any medication.
Comments